Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
Aim. To estimate ibrutinib efficacy in the treatment of first early CLL relapses and in patients with ≥ 2 lines of preceding therapy. Analysis of treatment results in patients with del(17p) and monitoring of minimal residual disease (MRD) and ibrutinib safety profile. Materials & Methods. The ana...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Russo |
| Pubblicazione: |
Practical Medicine Publishing House
2018-01-01
|
| Serie: | Клиническая онкогематология |
| Soggetti: | |
| Accesso online: | https://bloodjournal.ru/index.php/coh/article/view/349 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|